Bristol-Myers Squibb Rights
CELG.RT
16 hedge funds and large institutions have $150K invested in Bristol-Myers Squibb Rights in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
4% less capital invested
Capital invested by funds: $156K → $150K (-$5.96K)
11% less funds holding
Funds holding: 18 → 16 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$586 |
| 2 |
CCP
Carmel Capital Partners
San Diego,
California
|
-$66 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$41 |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$29 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3 |
CELG.RT Hedge Fund Activity: Q3 2023 in Review
16 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q3 2023, worth a combined $150K — down 3.8% from $156K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CELG.RT and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, cutting an estimated $586.
- 16 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q3 2023, down from 18 in Q2 2023.
- Funds reported $150K of Bristol-Myers Squibb Rights stock for Q3 2023, down 3.8% quarter-over-quarter.
- 0 funds opened new Bristol-Myers Squibb Rights positions in Q3 2023 and 2 closed out, a net change of -2 holders.
- The largest Bristol-Myers Squibb Rights seller in Q3 2023 was Susquehanna International Group, an estimated $586 sold.
Based on aggregated 13F filings for Q3 2023.